explore -WSS

explore

author：focus 2025-09-29 01:46:06 - browse：92853

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

WSS

AI used to predict Covid

Biohaven protein

Akili, maker of video game for ADHD, to be acquired for 34 million

Startling documents reveal new facets of Sacklers' opioid empire

Lab trade group sues FDA to halt regulation of lab

Merck, Daiichi strike cancer drug pact worth up to $22 billion

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

In age of alternative facts, a scholarly course on calling out crap

Readout LOUD podcast: Live from the 2023 STAT Summit

The high cost of giving birth even with insurance

STAT Summit: Ending the crisis of Black deaths in the U.S.

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why a market frenzy over new weight loss drugs defies logic

Virginia high school admissions case could be legal follow

Dark money group runs ads on China biotech bill

In age of alternative facts, a scholarly course on calling out crap

J&J lung cancer data amount to new salvo against AstraZeneca

focus

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Merck, Daiichi strike cancer drug pact worth up to $22 billion

CZI to create biohub to build anti

Average age of first period drops to 11.9 years, study shows

Roivant's CEO is a star, but biotech's black hole persists

The problems with dementia villages

leisure time

explore

hotspot

explore